Security key
74365A309
Protalix BioTherapeutics, Inc. - Common Shares (PLX)
CUSIP: 74365A309
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common Shares
- Total 13F shares
- 232,070
- Total 13F value
- $639,720
- Share change
- +131,171
- SEC-reported price per share
- $2.76
- Number of holders
- 11
- Value change
- +$362,086
- Number of buys
- 5
- Number of sells
- 3
- Shares outstanding
- 79,957,519
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
11
Top holders
10
PLX full security history
Ownership snapshot
Full 13F holder table
Protalix BioTherapeutics, Inc. SEC filings
Protalix BioTherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74365A309
Recent filing periods:
Ownership snapshot
Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
MAK Capital Fund LP
Comparable rows
2/15
Latest evidence
03 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 5%
13 rows are not safely comparable across share classes.
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 5%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 2
BlackRock, Inc.
5%
MAK Capital Fund LP
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
5%
Reported 13D/G
· 30 Jun 2026
|
$9,428,694
4,046,650 shares
|
$0 | 30 Jun 2026 |
| MAK Capital Fund LP |
13D/G
|
4.5%
Reported 13D/G
· 24 Mar 2026
|
$11,355,147
3,616,289 shares
|
-$3,244,593 | 24 Mar 2026 |
| Dexcel Pharma Technologies Ltd. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$5,128,613
3,637,314 shares
|
— | 02 Jun 2021 |
| Dror Bashan |
3/4/5
PRESIDENT AND CEO, Director
|
—
mixed-class rows
|
$4,772,163
3,012,934 shares
mixed-class rows
|
+$101,360 | 03 Sep 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$2,553,680
1,096,000 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
—
denominator unverified
|
$2,291,746
983,582 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
232,070
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
101
Q3 2026 holders
11
Holder diff
-90
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend